Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo (TES2022)
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial (TES2022)
Sponsor: Centers for Disease Control and Prevention
A PHASE4 clinical study on Uncomplicated Plasmodium Falciparum Malaria, this trial is completed. The trial is conducted by Centers for Disease Control and Prevention and has accumulated 8 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE4
Status: Active Not Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE4
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE4
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centers for Disease Control and Prevention
- Global Fund
- Ministry of Public Health, Democratic Republic of the Congo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boende, Democratic Republic of the Congo
- • Kabondo, Democratic Republic of the Congo
- • Kalima, Democratic Republic of the Congo
- • Kapolowe, Democratic Republic of the Congo
- • Kazumba, Democratic Republic of the Congo
- • Kimpese, Democratic Republic of the Congo
- • Vanga, Democratic Republic of the Congo